Human Metabolome Technologies, Inc. (hereinafter referred to as HMT, Head office: Tsuruoka City, Yamagata Prefecture, Chief Executive Officer: Ryuji Kanno,) and Pharmalegacy Laboratories (Shanghai) Co.,Ltd.（hereinafter referred to as PLS, Chief Executive Officer: Jeff Duan）announced a strategic partnership. The scope of partnership includes information sharing and co-operation in sales and marketing activities in order to help each other’s growth in overseas market.
China’s presence in bio science research and development has been dramatically increasing over the past few years. Against this background, HMT has started to provide metabolomics service in China to support academic and industry clients using our advanced technology and knowhow.
PLS is a leading specialty pharmacology contract research organization located in Shanghai Zhangjiang High-Tech Park, China, where many international and Chinese pharmaceutical companies have R&D laboratories. It is equipped with a world-class facility including AAALAC, working for international pharmaceutical industrial standards.
Mr. Ryuji Kanno, CEO of HMT says “we see great potential in metabolomics and biomarker diagnostics market in China. PLS has expertise in Chinese pharmaceutical market information and well-established access to pharmaceutical companies in and out of Shanghai. We believe that this can be a very successful, long-term win-win partnership. I am confident that this collaboration will enable us to serve pharmaceutical companies located in China more smoothly and boost our metabolomics service growth in China. We are also willing to provide necessary support for PLS’s growth in key markets where we have good footprint and presence.”
Dr. Jeff Duan, CEO of PLS says “drug design today is increasingly complex with each new therapy relying on specialized services that are economically beyond being justifiably established in-house. As Asia’s top provider of a broad range of very specialized service platforms, we are excited to bring the metabolomics service of HMT to our client base and being able to expand the reach of our service offering to the client base of HMT. ”
About Human Metabolome Technologies : Human Metabolome Technologies, Inc., (HMT) was founded in 2003 by Professor Masaru Tomita, Ph.D., Director of the Institute for Advanced Biosciences (IAB), Keio University, Japan, and by IAB’s Professor Tomoyoshi Soga, Ph.D. A Japan-based biotechnology company, HMT provides capillary electrophoresis mass spectrometry-based metabolomics services, aiming to provide complete solutions for metabolomics research in biomarker discovery, drug design, diagnostic technology and food production.
About Pharmalegacy Laboratories (Shanghai):
PharmaLegacy provides preclinical in vivo pharmacology efficacy services as well a therapeutic antibody discovery service program. Our state-of-the-art platforms include
• Pioneering work using CD34+ humanized mice that carry a human immune system, to test biologics for immuno-oncology therapeutic efficacy
• Fresh human tumor 3D tissue culture platform
• An NHP platform for therapeutic biologics testing in a variety of immune diseases
• An advanced antibody discovery platform based on single B cell antibody screening
• An internationally recognized Bone/Orthopaedics platform to test both hard tissue disease therapeutic candidates and medical devices
Plus over 300 clinically predictive animal disease models to evaluate pharmacological effects of drug candidates in the areas of inflammation/auto-Immune diseases, lung injury, liver/metabolic diseases and oncology.
Our NHP platform and CD34+ humanized mice models have helped dozens of clients with IND filings to both FDA and CFDA (China) for their therapeutic biologics candidates in a variety of immune disease and oncology. Our animal vivarium is fully accredited by AAALAC and houses species ranging from rodents, rabbits and other small animals to NHP.